UY33525A - Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición - Google Patents

Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición

Info

Publication number
UY33525A
UY33525A UY0001033525A UY33525A UY33525A UY 33525 A UY33525 A UY 33525A UY 0001033525 A UY0001033525 A UY 0001033525A UY 33525 A UY33525 A UY 33525A UY 33525 A UY33525 A UY 33525A
Authority
UY
Uruguay
Prior art keywords
new
interferon
stable
ifn
conjugate
Prior art date
Application number
UY0001033525A
Other languages
English (en)
Inventor
Denisov Lev Aleksandrovich
Morozov Dmitriy Valentinovich
Rudenko Elena Georgievna
Klenova Angelina Vsovoldovna
Chernovskaya Tatyana Veniaminovna
Original Assignee
Cjsc Biocad
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=45497062&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33525(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cjsc Biocad filed Critical Cjsc Biocad
Publication of UY33525A publication Critical patent/UY33525A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/555—Interferons [IFN]
    • C07K14/56—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Nuevos PEG-derivados del interferón y se vincula a la creación de un nuevo conjugado de interferón con polietilenglicol, activo, altamente purificado , estable, a la actividad del interferón alfa, con inmunogenicidad reducida, a una acción biológica prolongada, a parámetros farmacocinéticos mejorados de la fórmula general dónde: n - valores enter os del 227 al 10000; m - número entero Z4; IFN - polipéptido natural o recombinante, con actividad IFN-alfa. Asimismo, se relaciona con fármacos que contienen el conjugado de la fórmula (I), con farmacos, adecuados para tratar enfermedades virales, oncológicas y enfermedades inmunodeficiencia primaria o secundaria, que contienen el conjugado solicitado PEG-IFN y componentes auxiliares.
UY0001033525A 2010-07-20 2011-07-20 Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición UY33525A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2010129824/10A RU2447083C1 (ru) 2010-07-20 2010-07-20 НОВЫЙ ФУНКЦИОНАЛЬНО АКТИВНЫЙ ВЫСОКООЧИЩЕННЫЙ СТАБИЛЬНЫЙ КОНЪЮГАТ ИНТЕРФЕРОНА α С ПОЛИЭТИЛЕНГЛИКОЛЕМ, ПРЕДСТАВЛЕННЫЙ ОДНИМ ПОЗИЦИОННЫМ ИЗОМЕРОМ ПЭГ-NαH-ИФН, С УМЕНЬШЕННОЙ ИММУНОГЕННОСТЬЮ, С ПРОЛОНГИРОВАННЫМ БИОЛОГИЧЕСКИМ ДЕЙСТВИЕМ, ПРИГОДНЫЙ ДЛЯ МЕДИЦИНСКОГО ПРИМЕНЕНИЯ, И ИММУНОБИОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ

Publications (1)

Publication Number Publication Date
UY33525A true UY33525A (es) 2012-02-29

Family

ID=45497062

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033525A UY33525A (es) 2010-07-20 2011-07-20 Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición

Country Status (20)

Country Link
KR (1) KR101586372B1 (es)
CN (1) CN102617736B (es)
AR (1) AR087227A1 (es)
BR (1) BRPI1101565A2 (es)
CO (1) CO6680611A2 (es)
CR (1) CR20130021A (es)
CU (1) CU24193B1 (es)
DO (1) DOP2013000002A (es)
EA (1) EA020257B1 (es)
EC (1) ECSP13012398A (es)
HK (1) HK1170504A1 (es)
MX (1) MX2011007458A (es)
MY (1) MY168784A (es)
NI (1) NI201300008A (es)
PE (1) PE20131034A1 (es)
RU (1) RU2447083C1 (es)
SG (1) SG187117A1 (es)
UA (1) UA99766C2 (es)
UY (1) UY33525A (es)
WO (1) WO2012011836A1 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2515913C1 (ru) * 2013-03-22 2014-05-20 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт генетики и селекции промышленных микроорганизмов" (ФГУП "ГосНИИгенетика") ГИБРИДНЫЙ БЕЛОК, ОБЛАДАЮЩИЙ ПРОЛОНГИРОВАННЫМ ДЕЙСТВИЕМ, НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2 ЧЕЛОВЕКА (ВАРИАНТЫ), СПОСОБ ЕГО ПОЛУЧЕНИЯ И ШТАММ Saccharomyces cerevisiae ДЛЯ ОСУЩЕСТВЛЕНИЯ ЭТОГО СПОСОБА (ВАРИАНТЫ)
EA021643B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Монопегилированный интерферон-альфа линейной структуры и фармацевтическая композиция для приготовления лекарственного средства, обладающего активностью интерферона-альфа
EA021610B1 (ru) * 2013-03-28 2015-07-30 Илья Александрович МАРКОВ Жидкое противовирусное лекарственное средство
CN103463623B (zh) * 2013-09-03 2015-09-09 长春海伯尔生物技术有限责任公司 一种聚乙二醇干扰素注射液及其制备方法
RU2554761C1 (ru) * 2014-05-13 2015-06-27 Закрытое акционерное общество "Сибирский центр фармакологии и биотехнологии" Противоэнтеровирусное и иммуностимулирующее средство
RU2572800C1 (ru) * 2014-09-22 2016-01-20 Закрытое Акционерное Общество "Биокад" Новый состав, содержащий конъюгат пэг и интерферон-альфа-2бета, обладающий сниженной болезненностью при введении
EA029498B1 (ru) * 2015-11-24 2018-04-30 Учреждение Белорусского государственного университета "Научно-исследовательский институт физико-химических проблем" (НИИ ФХП БГУ) ПРОТИВООПУХОЛЕВОЕ СРЕДСТВО НА ОСНОВЕ РЕКОМБИНАНТНОГО ИНТЕРФЕРОНА АЛЬФА-2b В ВИДЕ МИКРОЧАСТИЦ ДЛЯ ПАРЕНТЕРАЛЬНОГО ПРИМЕНЕНИЯ
RU2678332C1 (ru) 2017-09-08 2019-01-28 Общество с ограниченной ответственностью "Саентифик Фьючер Менеджмент" (ООО "СФМ") Пегилированный интерферон лямбда, обладающий высокой биодоступностью при пероральном применении, и способ его получения
AU2021258734A1 (en) * 2020-04-20 2023-01-05 Altum Pharmaceuticals Inc. Recombinant interferon
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5951974A (en) * 1993-11-10 1999-09-14 Enzon, Inc. Interferon polymer conjugates
US20030053982A1 (en) * 1994-09-26 2003-03-20 Kinstler Olaf B. N-terminally chemically modified protein compositions and methods
JP2758154B2 (ja) * 1995-04-06 1998-05-28 エフ・ホフマン−ラ ロシユ アーゲー インターフェロンを含む液体製剤
TW517067B (en) * 1996-05-31 2003-01-11 Hoffmann La Roche Interferon conjugates
RS20050202A (en) * 2002-09-09 2007-08-03 Nektar Therapeuticals Al.Corporation, Water-soluble polymer alkanals
RU2311930C2 (ru) * 2004-04-30 2007-12-10 Закрытое акционерное общество "ВЕРОФАРМ" Пэгилированный интерферон для борьбы с вирусной инфекцией
CA2572751A1 (en) * 2004-06-30 2006-01-12 Egen Corporation Pegylated interferon alpha-1b
US7872082B2 (en) * 2005-07-19 2011-01-18 Nektar Therapeutics Method for preparing polymer maleimides
JP2009541333A (ja) * 2006-06-23 2009-11-26 クインテセンス バイオサイエンシーズ インコーポレーティッド 修飾リボヌクレアーゼ
CN101491682A (zh) * 2008-04-30 2009-07-29 北京凯正生物工程发展有限责任公司 聚乙二醇化重组人干扰素ω偶合物及其制备工艺
CN101591387A (zh) * 2008-05-28 2009-12-02 中国人民解放军军事医学科学院微生物流行病研究所 聚乙二醇化重组人干扰素ω偶合物
CN101514229B (zh) * 2009-04-03 2012-05-09 海南四环心脑血管药物研究院有限公司 人干扰素α衍生物及其聚乙二醇化修饰物

Also Published As

Publication number Publication date
CU20130013A7 (es) 2013-04-19
EA020257B1 (ru) 2014-09-30
KR101586372B1 (ko) 2016-01-18
HK1170504A1 (zh) 2013-03-01
MX2011007458A (es) 2012-01-19
KR20130056885A (ko) 2013-05-30
BRPI1101565A2 (pt) 2012-12-04
ECSP13012398A (es) 2013-05-31
SG187117A1 (en) 2013-02-28
CN102617736B (zh) 2015-11-25
CN102617736A (zh) 2012-08-01
CR20130021A (es) 2013-02-20
WO2012011836A1 (en) 2012-01-26
RU2010129824A (ru) 2012-01-27
DOP2013000002A (es) 2013-09-15
PE20131034A1 (es) 2013-09-27
AR087227A1 (es) 2014-03-12
CO6680611A2 (es) 2013-05-31
NI201300008A (es) 2014-05-26
CU24193B1 (es) 2016-09-30
MY168784A (en) 2018-12-04
RU2447083C1 (ru) 2012-04-10
UA99766C2 (uk) 2012-09-25
EA201100809A1 (ru) 2012-01-30

Similar Documents

Publication Publication Date Title
UY33525A (es) Nuevo polietilenglicol, estable conjugado de interferón alfa, representado por un isómero de posición
CO6501124A2 (es) Polipeptidos inmunomoduladores derivados se la il 2 y su uso terapeutico en cancer y en infecciones crónicas
CL2017001089A1 (es) Vacunas terapéuticas contra el vph16
EA201490801A1 (ru) Композиции этанерцепта, стабилизированные комбинациями сахаров и полиолов
BR112013031268A8 (pt) polipeptídeos
AR083162A1 (es) Uso de ingredientes activos para controlar nematodos en cultivos resistentes a nematodos
WO2013002580A3 (ko) 폴리에틸렌글라이콜 또는 이의 유도체로 페길화된 엑센딘-4 유사체, 이의 제조방법 및 이를 유효성분으로 함유하는 당뇨병 예방 또는 치료용 약학적 조성물
UY33025A (es) Composicion farmaceutica que comprende un agonista de glp-1 metionina
CL2011000170A1 (es) Composicion farmaceutica solida y estabilizada que comprende un ingrediente farmaceuticamente activo, oxido de titanio y un plastificante; procedimiento para estabilizar la composicion farmaceutica durante una irradiacion luminosa.
CL2011000571A1 (es) Uso de una combinacion de: a) un compuesto de formula (1) o una sal farmaceuticamente aceptable del mismo, b) interferon alfa y c) ribavirina para preparar un medicamento util para el tratamiento de una infeccion viral de la hepatitis c (hcv) o para aliviar uno o mas sintomas de la misma.
BR112014032990A2 (pt) seringa
BR112012011128A2 (pt) composição farmacêutica compreendendo um agonista de glp-1, uma insulina e uma metionina
EA201492290A1 (ru) Составы и способы для вагинальной доставки антипрогестинов
MX2013005478A (es) Compuestos heterociclicos condensados antivirales.
EA201491479A1 (ru) Производные лупановых тритерпеноидов и их фармацевтическое применение
DOP2012000030A (es) Polipéptidos del factor ix modificados y usos de los mismos
PE20130379A1 (es) Metodos para el tratamiento de las ulceras del pie diabetico
ECSP11011101A (es) Compuestos cicloundecadepsipéptidos y el uso de dichos compuestos como un medicamento
UY38069A (es) Péptidos de la cadena b de la relaxina lipidados modificados y su uso terapéutico
CR11734A (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
AR114323A1 (es) Péptidos de la cadena b de la relaxina modificados y su uso terapéutico
AR089812A1 (es) Agente terapeutico para la diabetes mellitus
AR086207A1 (es) Composiciones y metodos
BR112014009165A2 (pt) sal e uso médico
EA201391063A1 (ru) Аполипопротеин a-iv в качестве антидиабетического пептида